Brief: ADC Therapeutics Announces Amended Healthcare Royalty Financing Agreement

ADC Therapeutics SA

23/02/2026 12:28

Feb 23 (Reuters) - ADC Therapeutics SA ADCT.N:

ADC THERAPEUTICS ANNOUNCES AMENDED HEALTHCARE ROYALTY FINANCING AGREEMENT

ADC THERAPEUTICS SA - AGREEMENT REDUCES CHANGE OF CONTROL PAYMENT TO $150 MILLION THROUGH 2027

ADC THERAPEUTICS SA - HEALTHCARE ROYALTY GRANTED WARRANTS TO PURCHASE ABOUT 9.8 MILLION COMMON SHARES, WITH EXERCISE PRICE OF $3.81 PER SHARE

ADC THERAPEUTICS SA - ANTICIPATE MEANINGFUL GROWTH BEGINNING 2027, POTENTIAL PEAK REVENUE IN US COULD REACH $600 MILLION TO $1 BILLION ANNUALLY

ADC THERAPEUTICS SA - IN EVENT OF CHANGE OF CONTROL, HEALTHCARE ROYALTY WILL CONTINUE TO RECEIVE ROYALTIES BY ACQUIRER UNTIL ORIGINAL CAP IS REACHED

Source text: ID:nPn2D9yHSa

Further company coverage: ADCT.N

 ((Reuters.Briefs@thomsonreuters.com;))